🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the effort against drug-resistant strains of the infection, according to scientists.

An International Health Concern

Cases of gonorrhoea are increasing worldwide, with data suggesting over 82 million instances per year. Notably increased rates are observed in the African continent and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an important and timely advancement in the reality of growing infection rates, the spread of superbugs and the very limited treatment choices currently available.”

Health officials are increasingly worried about the increase in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program revealed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Clearance

One new antibiotic, also known as Nuzolvence, was cleared by the US FDA in December for use against gonorrhoea. This STI can lead to major issues, including infertility. Researchers hope that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, also received approval in the same week. This medication, which is also used to treat urinary tract infections, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to develop it.

“This approval signifies a significant shift in the treatment of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Testing Results and Worldwide Availability

Based on data released by a prominent scientific publication, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the current standard treatment, which combines a dual-drug approach. The research enrolled over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the rights to register and commercialise the drug in a wide range of low-income and middle-income countries.

Clinicians directly involved have shared positive views. Access to a single-dose, oral treatment like this is hailed as a "revolutionary step" for managing the epidemic. This is viewed as crucial to reduce the burden of the disease for patients and to halt the transmission of extremely resistant gonorrhoea around the world.